Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells

Lignende værker

• Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma
  af: Jessie Villanueva, et al.
  Udgivet: (2013-09-01)
• Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma
  af: Villanueva, Jessie, et al.
  Udgivet: (2013)
• BRAF Mutation-selective Inhibition of Thyroid Cancer Cells by the Novel MEK Inhibitor RDEA119 and Genetic-potentiated Synergism with the mTOR Inhibitor Temsirolimus
  af: Liu, Dingxie, et al.
  Udgivet: (2010)
• The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAF(V600E) Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells
  af: Liu, Ruixin, et al.
  Udgivet: (2012)
• BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers
  af: Sanchez, Jaquelyn N., et al.
  Udgivet: (2018)